News

ELCC: Survey reveals worldwide underuse of EGFR-mutation testing

Publish date: May 19, 2015

 

AT ELCC 2015

References

The survey was sponsored by Boehringer Ingelheim. Dr. Spicer has been an advisor to and speaker on behalf of Boehringer Ingelheim and had received research funding from the company. Dr. Mok has been a consultant to and speaker on behalf of Boehringer Ingelheim as well as several other drug companies.

mzoler@frontlinemedcom.com

On Twitter @mitchelzoler

Pages

Recommended Reading

AACR: KEYNOTE-001 takes step toward PD-L1 blocker biomarker
MDedge Hematology and Oncology
ELCC: NSCLC mutation testing highlights ctDNA’s limitations
MDedge Hematology and Oncology
ASA: Tumors glow green in new ‘optical biopsy’ technique
MDedge Hematology and Oncology
Lung adenocarcinoma subtype predicts benefit from adjuvant chemotherapy
MDedge Hematology and Oncology
New agent targets EGFR resistance in NSCLC
MDedge Hematology and Oncology
Rociletinib active against resistant NSCLC
MDedge Hematology and Oncology
ELCC: Urine tumor DNA shows high testing promise
MDedge Hematology and Oncology
Statin use associated with reduced lung cancer mortality
MDedge Hematology and Oncology
Health professionals’ attitudes toward the detection and management of cancer-related anorexia-cachexia syndrome, and a proposal for standardized assessment
MDedge Hematology and Oncology
VIDEO: Level of e-cigarette power contributes to potentially hazardous effects
MDedge Hematology and Oncology